CNSX:BUX Biomark Diagnostics (BUX) Stock Price, News & Analysis → Major Elon Musk Crypto Leak Revealed (From Crypto 101 Media) (Ad) Free BUX Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume11,500 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Biomark Diagnostics alerts: Email Address Ad WealthPressA lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. Click here to jump in on the next one About Biomark Diagnostics Stock (CNSX:BUX)BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis. The company was incorporated in 2014 and is headquartered in Richmond, Canada. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.Read More Ad DTIWarning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…Watch the presentation here BUX Stock News HeadlinesFebruary 28, 2024 | finance.yahoo.comBioMark Partners with Rubix LS to Advance Blood-Based Cancer Screening in Underserved CommunitiesFebruary 26, 2024 | finance.yahoo.comTheresa Peterson Joins Biomark's Advisory TeamMarch 29, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. February 20, 2024 | fortune.comQuest DiagnosticsDecember 29, 2023 | finanznachrichten.deBioMark Diagnostics, Inc.: BioMark Announces Closing of $1.9 Million Non-Brokered Private PlacementDecember 29, 2023 | finance.yahoo.comBioMark Announces Closing of $1.9 Million Non-Brokered Private PlacementDecember 4, 2023 | markets.businessinsider.comBioMark Announces Recent New Patent Granted in Canada to Support Its Liquid Biopsy Based Legacy AssayNovember 28, 2023 | finanznachrichten.deBioMark Diagnostics, Inc.: BioMark Provides Second Quarter Operational Update and Announces Extension to Warrant Exercise TermMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.November 14, 2023 | finance.yahoo.comBioMark Strengthens and Expands Its Strategic Advisory Team in Pursuit of Commercialization InitiativesOctober 24, 2023 | finance.yahoo.comBioMark to Unveil Results of Its Early Breast Cancer Study at the Upcoming San Antonio Breast Cancer SymposiumAugust 30, 2023 | finance.yahoo.comBioMark Appoints Kevin J. Cosgriff to Its Strategic Advisory TeamAugust 8, 2023 | finance.yahoo.comJapan Patent Office (JPO) Issued BioMark Patent with Claims Covering Its Lung Cancer Urine Based Liquid Biopsy AssayJuly 25, 2023 | finanznachrichten.deBioMark Diagnostics, Inc.: BioMark Issues Statement on Recent Market Activity and Provides a Brief Corporate UpdateJuly 25, 2023 | finance.yahoo.comBioMark Issues Statement on Recent Market Activity and Provides a Brief Corporate UpdateJuly 17, 2023 | mirror.co.ukGary Lineker and ex-stepdaughter Ella Bux put on a smiley display at WimbledonJune 5, 2023 | finance.yahoo.comBioMark Unveils Significant Scientific Advancements from Its Leading Liquid Biopsy Technology at ASCO 2023 Annual MeetingMay 31, 2023 | finance.yahoo.comBioMark Announces the U.S. Patent and Trademark Office Granted Patent with Claims Covering Its Lung Cancer Liquid Biopsy AssayMay 5, 2023 | marketwatch.comLiver Cancer Diagnostic Tests Market to Witness Huge Growth with Abbott Diagnostics, Abcodia, BioMark Technologies, AXO Science SASMay 3, 2023 | markets.businessinsider.comBioMark Latest Results Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023April 10, 2023 | msn.comCanadian Cancer Diagnostic Company BioMark Working On Early Lung Detection AssayMarch 16, 2023 | finanznachrichten.deBioMark Diagnostics, Inc.: BioMark Presents Novel Liquid Biopsy Data in Pulmonary Neuroendocrine TumorsMarch 16, 2023 | finance.yahoo.comBioMark Presents Novel Liquid Biopsy Data in Pulmonary Neuroendocrine TumorsMarch 1, 2023 | finanznachrichten.deBioMark Diagnostics, Inc.: BioMark Provides Third Quarter Operational Update and 2023 OutlookMarch 1, 2023 | finance.yahoo.comBioMark Provides Third Quarter Operational Update and 2023 OutlookJanuary 15, 2023 | barrons.comBioMark Diagnostics Inc.January 11, 2023 | ca.finance.yahoo.comBioMark Announces Update from Ongoing Clinical Trial Using Its Lung Cancer Liquid Biopsy Test as It Prepares for Commercial LaunchSee More Headlines Receive BUX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biomark Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeCNSX SectorMedical Industry Diagnostics & Research Sub-IndustryN/A Current SymbolCNSX:BUX CUSIPN/A CIKN/A Webwww.biomarkdiagnostics.com Phone604-370-0779FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Rashid Ahmed Maula Bux B.Sc.MBA, Founder, CEO, Pres & DirectorMs. Guoyu Huang MBAChief Financial OfficerMr. Brian Kai-Ming Cheng B.Sc.M.Sc, M.Sc., Chief Technical Officer & Independent DirectorDr. Jeff Haince Ph.D.GM & Chief Scientific OfficerNeal KaplanChief Financial Officer of USDr. Daniel SitarPrincipal Scientific AdvisorMore ExecutivesKey CompetitorsCharles River Laboratories InternationalCNSX:CRL45525 (CUR.TO)TSE:CURAbattis BioceuticalsCNSX:ATTAgraflora Organics InternationalCNSX:AGRAAmplify Alternative Harvest ETFCNSX:MJView All CompetitorsInsidersRashid Ahmed Maula BuxBought 1,100 shares on 3/15/2024Total: $330.00 ($0.30/share)Guoyu HuangBought 1,500 shares on 3/8/2024Total: $450.00 ($0.30/share)Rashid Ahmed Maula BuxBought 500 shares on 2/20/2024Total: $155.00 ($0.31/share)Rashid Ahmed Maula BuxBought 500 shares on 2/8/2024Total: $157.50 ($0.32/share)Rashid Ahmed Maula BuxBought 500 shares on 2/2/2024Total: $140.00 ($0.28/share) BUX Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Biomark Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biomark Diagnostics investors own include Stantec (STN) and IQE (IQE). How do I buy shares of Biomark Diagnostics? Shares of BUX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (CNSX:BUX) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingFed launches fourth dollar overhaulStansberry ResearchThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomark Diagnostics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.